Bristol Myers Squibb (BMY) Q2 2026 earnings review
Growth Engine Accelerates, Driving Massive Guidance Boost Despite Margin Contraction
Bristol Myers Squibb delivered a highly successful Q2, driven by a 15% revenue surge in its Growth Portfolio and surprisingly resilient performance from legacy blockbuster Eliquis. This top-line momentum prompted management to dramatically raise FY26 revenue guidance by roughly $2.75 billion at the midpoint and non-GAAP EPS by nearly $0.70. However, the beat masks an underlying profitability shift: gross margins contracted by 120 bps due to product mix, and management was forced to raise full-year operating expense guidance to $16.5B to fund the pipeline and commercial launches. While the company is successfully bridging the near-term generic gap, the looming 2027 patent cliff for Eliquis remains the dominant long-term overhang.
🐂 Bull Case
Management increased FY26 top-line guidance to $49.0-$50.0B (up from $46.0-$47.5B) and EPS to $6.75-$7.00. This indicates intense near-term commercial execution and robust demand.
The $7.6B Growth Portfolio now accounts for roughly 59% of total revenue, effectively offsetting the collapse of Revlimid and Pomalyst. Newer launches like Reblozyl (+29%), Breyanzi (+41%), and Camzyos (+60%) are delivering true blockbuster momentum.
🐻 Bear Case
Non-GAAP gross margin fell 120 bps YoY to 71.4%. The mix shift toward newer, partnered, and acquired assets is generating revenue growth but diluting overall profitability.
Legacy revenues fell just 4%, but this was entirely propped up by Eliquis surging 22%. With Eliquis facing a massive loss of exclusivity (LOE) step-down in 2027, the underlying Legacy cliff is far steeper than the Q2 print suggests.
⚖️ Verdict: 🟢
Bullish. Near-term execution is exceptional, and raising FY revenue guidance by nearly $3B mid-year is a powerful signal of commercial strength that outweighs current margin compression concerns.
Key Themes
Expanding Scale of the Growth Portfolio
BMS's primary strategy to survive the legacy patent cliff is executing flawlessly. The Growth Portfolio generated $7.56B, growing 15% YoY (14% ex-FX). Hematology anchors Reblozyl ($735M, +29%) and Breyanzi ($484M, +41%) are scaling rapidly, while Camzyos ($416M, +60%) is solidifying its position in cardiovascular. These are no longer emerging assets; they are foundational revenue drivers.
Subcutaneous Innovation: Opdivo Qvantig
The transition from IV Opdivo to the subcutaneous Qvantig formulation is accelerating faster than expected. Qvantig revenue surged to $261M (up from just $30M a year ago and $163M last quarter). This lifecycle management strategy is successfully defending the franchise from competitive erosion, keeping total Opdivo franchise revenue stable despite a 3% dip in IV sales.
Macro Tailwinds: Eliquis Defying the Cliff
Eliquis revenues surged 22% to $4.48B. Management previously guided that favorable pricing dynamics in the U.S. (driven by a WAC reduction that eliminated inflationary CPI penalties) would boost 2026 performance. This macro/pricing tailwind has materialized aggressively, leading management to double the Eliquis FY26 growth guidance from 10-15% to 20-25%.
Margin Compression Contradicts Productivity Narrative
Despite strong top-line beats, profitability metrics weakened. Non-GAAP gross margin contracted from 72.6% to 71.4% YoY due to product mix. Simultaneously, non-GAAP SG&A and R&D expenses both rose (8% and 2%, respectively), forcing management to raise full-year OpEx guidance by $200M. This cost creep contradicts the 'disciplined cost savings' narrative championed in late 2025.
The Brutal Reality of the Legacy Collapse
Excluding Eliquis, the Legacy Portfolio is evaporating rapidly due to generic entries. Revlimid collapsed 49% YoY to $425M, and Pomalyst plummeted 71% to $204M. While Eliquis's current outperformance masks this decay, Eliquis itself faces a guided $1.5B to $2B step-down in 2027. The Legacy safety net will not last.
Aggressive AI Integration to Accelerate R&D
BMS is making heavy investments in AI to improve R&D cycle times. The company announced a strategic agreement to deploy Anthropic's Claude across all enterprise functions, and an expansion of its NVIDIA partnership to utilize the Vera Rubin NVL72 AI infrastructure. This explicitly supports their stated goal of identifying lead molecules 50% faster and cutting development cycles by 30%.
Other KPIs
Decelerating. Down 120 basis points YoY from 72.6%. The company attributes this to a shift in product mix as the highly profitable legacy oncology brands (Revlimid/Pomalyst) are replaced by newer growth products and partnered assets.
Accelerating. Combined SG&A and R&D rose roughly 5% YoY. SG&A hit $1.83B (+8% YoY) driven by investments in new product launches, notably Cobenfy and Qvantig. This run-rate resulted in a $200M increase to full-year OpEx guidance.
Stable and improving. Total debt was reduced slightly while cash balances remain healthy, resulting in a net debt reduction from $34.0B at the end of FY25. The company retains significant financial flexibility for its $5B remaining share repurchase authorization and future business development.
Guidance
Accelerating. A massive $2.75 billion upward revision at the midpoint compared to previous guidance of ~$46.0 - $47.5 billion. Driven by broad-based momentum across the Growth Portfolio and Eliquis outperformance.
Accelerating. Raised significantly from the prior range of $6.05 - $6.35. The higher revenue base provides enough operational leverage to outpace the modest increase in planned operating expenses.
Accelerating. Raised from 10% - 15%. A combination of robust global volume demand and favorable net pricing dynamics in the U.S. is fueling what will likely be the peak revenue year for the asset.
Accelerating slightly. Raised from ~$16.3 billion to accommodate increased investments behind key pipeline programs and commercial support for new launches.
Key Questions
Gross Margin Floor
With non-GAAP gross margins compressing 120 bps this quarter entirely due to product mix, where does management see the margin floor settling once the high-margin legacy assets fully roll off in 2027?
Eliquis LOE Step-Down
Given that Eliquis growth is now expected to be 20-25% this year—meaning a much larger base going into 2027—does this alter the magnitude of the $1.5 to $2 billion revenue step-down previously guided for the 2027 European LOE?
OpEx Increases vs Productivity
Operating expense guidance was raised by $200 million despite the ongoing $2 billion strategic productivity initiative. Which specific pipeline assets or commercial launches are absorbing this incremental capital?
Qvantig Cannibalization
Opdivo Qvantig is scaling incredibly fast, reaching $261M this quarter. How much of this is pure cannibalization of IV Opdivo versus expansion into new patients or treatment durations?